Delphinus Medical Technologies, Inc. specializes in breast cancer screening using its FDA approved SoftVue™ 3D Whole Breast Ultrasound Tomography system, designed specifically for women with dense breasts.

Delphinus Medical Technologies, Inc.

Delphinus Medical Technologies, Inc. | 7,270 followers on LinkedIn. Delivering medical innovations to transform early detection of breast cancer and save women’s lives all over the world. | Delphinus Medical Technologies, Inc. is an innovation leader in advanced ultrasound development, introducing a dynamic new technique to image the breast with the use of sound and water. Headquartered in Novi, MI, Delphinus is the first company to design and manufacture a whole breast ultrasound system that utilizes a ring transducer to transmit and receive ultrasound signals. 

Called SoftVue™, and featuring proprietary TriAD™ (triple acoustic detection) technology,  the system captures reflection echoes from all directions around the breast and gathers transmitted signals coming through the breast.

Partner & Chief Operating Officer at Arboretum Ventures

Paul McCreadie

Medical Device Training and Education / Imaging and Ultrasound Radiology Training / Ophthalmic Surgery

Todd Philabaun

Engineering Vice President | Program & Product Management | Business & Brand Development | KOL Management | Process Improvement | R&D Leader

Rama Gundlapalli

Commercial and Sales Operations Executive - Delphinus Medical Technologies, Inc.

Mark Edwards

Happy Halloween from Team Delphinus! 🎃👻

Women with very dense breasts are 4 to 6 times more likely to get breast cancer, than women with fatty breast tissue. And on top of that, cancers in dense breast tissue can go undetected by mammography. Dense breast tissue can make it harder to detect abnormalities with mammography alone, which can delay critical early detection. That's where SoftVue™ comes in. Our FDA-approved 3D whole breast ultrasound technology increases cancer detection by up to 25% when used alongside mammography to screen women with dense breast tissue. This #BreastCancerAwarenessMonth , help your patients access the best tools for early detection. Have you experienced the impact of SoftVue™? Share your story! #Dense BreastAwareness #EarlyDetectionMatters #ThinkPink

“Do I have breast cancer?” Your patient’s question is quite simple. But with dense breast tissue, the answer often isn't so clear. #BreastCancerAwareness Month is a reminder of the importance of early detection - especially for women with dense breast tissue (nearly half of females older than 40). Mammography alone can miss key pathology, but SoftVue™ is changing that. Our cutting-edge 3D whole breast ultrasound technology can help find cancers hiding in dense tissue, increasing detection rates by up to 25%, when combined with a screening mammogram. With advanced imaging, designed specifically for dense breast tissue, SoftVue™ is setting a new standard in care. Let's ensure every woman has access to the best screening tools available. Learn how SoftVue™ revolutionizes breast cancer screening ➡️ https://lnkd.in/enyTrpzM #BreastCancerAwarenessMonth #InnovativeTech #DenseBreasts #EarlyDetectionMatters #ThinkPink

📅 It's Breast Cancer Awareness Month and we know you have preventative healthcare top-of-mind right now. Mammogram-only screening is outdated and misses up to 60% of cancer in women with dense breast tissue, which represent about half the female population. False or misleading screening tests can result in lost time and potentially missed opportunities to effectively diagnose early invasive breast cancer, and successfully treat it before it metastasizes to the lymph nodes and other parts of the body. 🩻 That's why Delphinus engineered and perfected ultrasound tomography to deliver the best in breast cancer screening technology: #SoftVue - where unparalleled comfort and maximum detection potential meet. When combined with annual mammograms, SoftVue™ offers women better screening accuracy that is 25% more effective than mammography by itself. 👩⚕️ If your patients are reluctant to get screened due to the reliability of mammography, then it's time you partner with us to put their minds at ease. Comment and share your patient SoftVue™ success stories and share this post with others in your healthcare network! #EarlyDetection #BreastCancerAwareness #WomensHealth #WomensHealthcare #ThinkPink #FightCancer #Pinktober

Today is Metastatic Breast Cancer Awareness Day and marks two years since SoftVue™ scanned its very first patient. Early detection is key to effectively treating breast cancer before it becomes metastatic and spreads to other parts of the body. SoftVue™'s advanced 3D whole breast ultrasound technology offers improved diagnostic accuracy when used in combination with mammography. SoftVue™ is also FDA-proven to help radiologists catch up to 25% more malignancies in women with dense breast tissue compared to using mammography alone - making it a life-saving addition to annual screening. Take a look back #OnThisDay in 2022, hearing directly from our first patient, Cheryl, about her experience: https://lnkd.in/eCTjy6PQ By detecting cancer earlier, SoftVue™ sees a future where fewer breast cancers become metastatic. Let’s continue to spread awareness and ensure every woman has access to the best screening technology. #MBCawareness #KickCancer #BreastCancerAwareness #EarlyDetectionSavesLives #InnovativeTech #DenseBreastAwareness

Hey, Austin, we’re heading your way! SoftVue™ is back on the go and coming to Round Rock, TX, later this month in partnership with ARA Diagnostic Imaging - Austin Radiological Association SoftVue™ is the only FDA-Approved tomographic ultrasound device that improves breast cancer detection when used in combination with mammography for your patients with dense breasts, helping to increase patient compliance with new screening guidelines. Mark your calendars for Oct 29-31, and reserve a spot to see this new, trail-blazing technology in action, engage in an image review session, and learn more about how SoftVue™ can set your practice apart from the competition. See through dense tissue with SoftVue™. RESERVE YOUR SPOT: ☑️Physicians: https://lnkd.in/e86np_A2 ☑️Patients: https://lnkd.in/eiJw3vAW #BreastCancerScreening #BreastCancerAwareness #AustinTexasHealthcare #TXHospitalAdmins #AustinHealthcare #ATXHealth #AustinHealthSystems #ATXDoctors #AustinMedicine #HospitalManagement

Yesterday #TeamDelphinus spent the last day of summer at Gilbert Willis Park in Wixom. We enjoyed an amazing BBQ cooked on-site by Mainstreet Catering. 🍔🍻 The team engaged in a variety of outdoor games and activities and participated in a Cornhole Tournament – congrats to our winning team! 🥇 Featuring a fun visit from an ice cream truck and a caricaturist that joined us for fun drawings for all. 🍦🧑🎨 It was a beautiful day to honor and show appreciation to our team members for their hard work and dedication to our company and mission. Thanks for all you do! #teambonding #companypicnic #employeeappreciation

📢 New FDA Mandate Alert! As of September 10, 2024, mammogram facilities must inform patients if they have dense breast tissue—a key step for earlier breast cancer detection. Dr. Natalie Azar explains how this change could save lives. Watch the TODAY Show segment here: https://lnkd.in/eeCb8Qws At Delphinus Medical Technologies, our SoftVue imaging is designed to help, offering cutting-edge solutions for dense breast tissue. Learn more: https://lnkd.in/e_B5tpiy #BreastCancerAwareness #EarlyDetection #SoftVue #DelphinusMedicalTech #DenseBreasts #DenseBreastLegislation

Domain Not Resolving

Google Maps

Amazon

Mobile Non Scaleable Content

DNSSEC

Amazon Virginia Region

reCAPTCHA v2

jQuery CDN

Microsoft

Chief Medical Officer

Peter Littrup

Chief Financial Officer

Shawn O'Brien

Marketing Manager

Corinne Duluk

Director of Clinical Engineering

Cuiping Li

Sales and Support

Daniel Plotkin

Director of Software Engineering

Erik West

Jonathan Moeser

Human Resources Manager & Executive Assistant to CEO

Katie Boyington

Director of Finance

Rachel Brown

James Prowse

Robert Cesaro

Debra Saunders

Michael Gross

Heather Rone

Hugo Braun

Ronald Schilling

Neb Duric

Co-Founder & CTO

Peter J. Littrup

Michael Emery

Scott A. White

Chief Executive Officer and President

Vice President of Engineering

Medical Device Companies With More Than 50 Employees

University of Michigan Alumni Founded Companies

United States Companies With Less Than $10M in Revenue (Top 10K)

Biotechnology Companies With Fewer Than 100 Employees (Top 10K)

Delphinus Medical Technologies develops, commercializes, sells, and services breast cancer screening solutions to hospitals and imaging clinics in the United States and internationally. It commercializes SoftVue, a three-dimensional and tomographic ultrasound imaging and risk assessment device that examines women's breasts for the presence of benign and/or malignant masses, assesses breast cancer risks, diagnoses breast diseases, and monitors therapy.

Trinity Capital

Venture Round - Delphinus Medical Technologies

Arboretum Ventures

Series D - Delphinus Medical Technologies

Series C - Delphinus Medical Technologies

Venture Investors

Series B - Delphinus Medical Technologies

Beringea

Series A - Delphinus Medical Technologies

Novi

Michigan

United States

North America

Delphinus Medical Technologies

Delphinus Medical Technologies Awarded Technology Breakthrough From Premier, Inc.

West Jefferson Medical Center Joins Growing Group of Imaging Centers Installing SoftVue Breast Ultrasound Tomography

Delphinus Announces Installation of Its SoftVue Breast Ultrasound Tomography System at McLeod Regional Medical Center

Study Shows Advantage Of Delphinus Medical's SoftVue UST In Breast Cancer Detection

Delphinus Medical Technologies in Novi Names Rama Gundlapalli Vice President of Engineering

Delphinus Medical Technologies Hires New Chief Financial Officer, Michael Emery

Delphinus Adds Dr. Elise Berman as New Medical Director to Executive Team

Delphinus Adds Dr. Elise Berman as New Medical Director to Growing Executive Team

Delphinus Medical Technologies Hires New VP of Engineering

India

Asia

The Netherlands

Europe

HTML5

Google Tag Manager

F5 NGINX

Modernizr

Cloudflare CDN

Vimeo

Google Drive

Wordpress

jQuery

Google Doubleclick

Delphinus Medical Technologies develops breast cancer screening technologies, including the SoftVue™ 3D Whole Breast Ultrasound Tomography system, designed for dense breast tissue, and is approved by the FDA.

news impact assignment basic	general
public peers	general	Nov 5, 2024 10:23 PM	1c597a44
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Nov 5, 2024 10:23 PM	9915c3d4
crunchbase trigger	general	Nov 5, 2024 10:23 PM	f4d2306d
crunchbase profile	general	Nov 2, 2024 9:57 PM	8dcea286
li profile	general	Nov 5, 2024 10:23 PM	038cac23
translate crunchbase fundingrounds	general	Nov 6, 2024 3:12 PM	6c476561
peers	general	Nov 5, 2024 10:23 PM	317e1eda
news basic	general	Nov 5, 2024 10:23 PM	0a8266cd
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

DELP

COM:DELPHINUSMT

Delphinus Medical Technologies, Inc.